Tissue specific tumour transition needs few cells
German researchers have modeled when cellular alterations inevitably lead to the development of cancer. The transition is tissue-specific and needs only a few cells.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1185 entries already.
Entries by Thomas Gabrielczyk
Drug dissociates metastasis precursors in blood
/in News/by Thomas GabrielczykA team of Swiss researchers has identified Na+/K+-ATPase blockers as candidate drugs capable to prevent formation of metastases. In blood, the repurposed drugs identified in a screening dissociated clusters of circulating […]
Policymakers take no action after ECJ mutagenesis ruling
/in News/by Thomas GabrielczykIn summer the European Court of Justice (ECJ) ruled that crops created by biological mutagenesis techniques fall under EU GMO legislation. Germanys government and the European Parliament see no need […]
Sandoz antiinfectives partner Ares Genetics gets fund
/in News/by Thomas GabrielczykJust in mid-December, antibiotic resistance detection expert Ares Genetics (Vienna, Austria) inked an agreement with Sandoz to use its pathogenome database and bio-IT know-how to develop repurposed and novel antiinfectives that […]
AI provides face read-out of genetic diseases
/in News/by Thomas GabrielczykExperts in artificial intelligence (AI) have created another problem for bioethicists and data protection specialists: their algorithm has learned to identify people with rare genetic syndromes from facial images.
Endothelial disruption: From bench to bedside
/in News/by Thomas GabrielczykBio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency […]
Sanofi ends immuno-oncology discovery with Regeneron
/in News/by Thomas GabrielczykSanofi and Regeneron announced they have "restructured" their US$2,17bn immunoncology collaboration. While the companies will continue co-marketing of the FDA approved (2018) PD1 blocker cemiplimab (REGN2810) as treatment for cutaneous squamous […]
Diverse cells make up the endothelium
/in News/by Thomas GabrielczykCells that line the blood vessels do not behave identically but instead exhibit varied responses to the same biochemical signals, British researchers report in Science.
Microbiome defines gut conditions
/in News/by Thomas GabrielczykDifferences in microbiome composition can help to distinguish inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), Dutch and US researchers report.
Cellestia Biotech AG attracts Series A financing
/in News/by Thomas GabrielczykCancer specialist Cellestia Biotech AG has secured CHF20m through a Series A financing led by FC Capital, and PPF / Sotio, and ETP Ventures, Boston & Beijing.